Pharmacological Management of Urinary Disorders

Introduction to Amitriptyline

• The American Urological Association recommends amitriptyline for Interstitial Cystitis/Bladder Pain Syndrome with Grade B evidence strength 1
• Effective dosing of amitriptyline for Interstitial Cystitis/Bladder Pain Syndrome starts at low doses (10 mg) and titrates gradually to 75-100 mg if tolerated 1
• Amitriptyline helps with pain management and may reduce urinary frequency in Interstitial Cystitis/Bladder Pain Syndrome 1

Alpha-Blockers for Benign Prostatic Hyperplasia (BPH)

• The American Urological Association notes that alpha-1A receptors are the predominant subtype in the prostate, representing approximately 70% of total alpha-1 receptor mRNA, and are responsible for prostatic smooth muscle contraction, with stimulation increasing outlet resistance, making them a target of alpha-blockers used in BPH treatment 2
• Alpha-1 receptors are present but in lower density compared to the prostate, concentrated at the bladder neck and proximal urethra, according to the European Association of Urology 3
• Stimulation of alpha-1A receptors causes prostatic smooth muscle contraction, increased bladder outlet resistance, and contributes to symptoms of BPH, as stated by the American Urological Association 2
• The European Association of Urology recommends that alpha-blockers for BPH target primarily alpha-1A receptors in the prostate, with alfuzosin, doxazosin, tamsulosin, and terazosin being effective options, and silodosin having higher selectivity for alpha-1A receptors 2, 4, 5
• These medications reduce prostatic smooth muscle tone and improve urinary flow, as noted by the European Urology association 5
• Alpha-1A selectivity may provide better relief of obstructive symptoms with fewer cardiovascular side effects, according to the American Urological Association 4
• Common side effects of alpha-blockers include orthostatic hypotension (more common with less selective agents like doxazosin and terazosin), ejaculatory dysfunction (more common with highly alpha-1A selective agents like silodosin), and intraoperative floppy iris syndrome (associated with all alpha-blockers during cataract surgery), as reported by the European Association of Urology 4